FINWIRES · TerminalLIVE
FINWIRES

研究快訊:梯瓦製藥第一季業績:創新成長驅動業績,克服仿製藥逆風

By

-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下:梯瓦製藥2026財年第一季業績穩健,營收達39.82億美元(年增2%),非GAAP每股收益為0.53美元,超出市場普遍預期的0.46美元。創新產品組合推動了成長,其中主要品牌營收達8.38億美元(年成長41%),主要品牌包括AUSTEDO(5.78億美元,較去年同期成長41%)、AJOVY(1.96億美元,年成長35%)和UZEDY(6,300萬美元,年成長62%)。神經科學產品的強勁成長動能顯示梯瓦製藥「轉型成長」策略的成功,有效抵消了來那度胺仿製藥競爭的不利影響。管理階層維持2026年營收預期在164億美元至168億美元之間,但因以7億美元策略性收購Emalex Biosciences,每股盈餘預期上調至1.91美元至2.11美元。此次收購Emalex Biosciences將為Teva帶來首創的兒童圖雷特症候群治療藥物ecopipam,預計將於2026年下半年提交新藥申請。我們認為此次收購符合Teva的神經科學策略,並代表資本效率更高的產品線擴張;但由於預計會產生研發費用,短期內利潤率將受到影響。

Related Articles

Research

Research Alert: CFRA Maintains Buy Opinion On Shares Of Visa Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our 12-month target price by $20 to $440, valuing shares at 29.5x our FY 27 (Sep.) EPS, a modest premium to Visa's five-year historical average of 29.1x. We increase our FY 26 EPS estimate to $13.21 from $12.95 and raise FY 27's to $14.94 from $14.66. AI is benefiting Visa more than disrupting it. Value-added services continue their strong momentum, growing 27% in the March quarter, significantly faster than overall revenue growth of 17%. Additionally, cross-border volumes have held steady despite geopolitical tensions in Iran, while payments volume is accelerating. Competitive dynamics are also improving. Revenue growth has outpaced client incentive growth in three of the past four quarters, reversing the previous five years, when client incentives consistently grew faster than revenues. Looking ahead, Visa's positioning as a leader in agentic commerce suggests continued strength, led by rising transaction counts and expanding value-added service adoption.

$V
US Markets

Brent Approaches $120 Per Barrel as Trump Reportedly Rejects Iranian Proposal

Oil prices rallied Wednesday, with Brent approaching $120 per barrel after US President Donald Trump reportedly rejected an Iranian proposal to lift the naval blockade.Brent crude was last up 7.2% at $119.25 per barrel, having traded as high as $119.45 earlier in the day. West Texas Intermediate rose 7% to $106.91.Trump told Axios on Wednesday he will maintain the US naval blockade of Iranian ports until Tehran agrees to a nuclear deal. Iran wanted the Strait of Hormuz opened before the two sides could sit down to discuss uranium enrichment at a later stage.In a social media post on Wednesday, Trump said Iran "better get smart soon."A senior Iranian security source told state media Press TV that the US naval blockade will soon be met with "practical and unprecedented action."The rhetoric comes amid stalled peace negotiations between Washington and Tehran, though their ceasefire agreement appears to be holding. A separate truce deal is in place between Israel and Lebanon.Pakistani mediators expect a revised proposal from Iran by Friday, CNN reported."Crude oil has resumed its war-driven rally, with Brent rising almost non-stop since a brief mid-month tumble to ($86 per barrel), when hopes for a peace deal and a short-lived reopening of the Strait of Hormuz triggered a sharp but temporary correction," Saxo Bank Head of Commodity Strategy Ole Hansen said in a report Wednesday.Besides the Iran war, markets are assessing the implication of the United Arab Emirates' decision to leave the Organization of the Petroleum Exporting Countries.The move marks a "major strategic shift (for the UAE), freeing it from production quotas that for years limited its ability to fully utilize expanding capacity," Hansen said.The UAE is set to increase oil production after walking away from oil cartel OPEC, ING Bank said in a report Wednesday."However, before this can be tapped, there must be a resolution in the Persian Gulf that allows for uninhibited energy flows through the Strait of Hormuz once again," ING said. "Therefore, in the short term, this development has little impact on the market. But in the medium to longer term, it means more supply for the market."

Australia

Pentair Stock Decline on Potential Inventory Destocking 'Overdone,' RBC Says

Pentair (PNR) shares fell 10% following the company's Q1 earnings report on Tuesday but the sell off, tied to warnings of a potential inventory destocking, was "overdone," RBC Capital Markets said.During the company's earnings call, Pentair disclosed expectations for its Pool channel partners to execute an inventory reduction in Q2 and Q3, which stems from a lowered industry volume forecast, especially for high-end discretionary products, the RBC analysts said. Pentair explained that recent price actions had prompted distributors to stock up, the analysts said.The stock price decline was also driven by H2-weighted guidance and concerns over residential and consumer spending, according to the note.However, Pentair continues its strong execution on productivity initiatives, margin improvement, and new product introductions, fueling a streak of 16 consecutive quarters of margin expansion, the analysts noted. They said that they have not observed any execution issues or missteps.RBC maintained the company's stock rating at outperform and lowered the price target to $101 from $107.Price: $81.36, Change: $-1.50, Percent Change: -1.81%

$PNR